New CRISPR approach may open path to hepatitis E treatment by blocking viral RNA

Researchers at the Ruhr University Bochum have developed a novel antiviral concept: Using the CRISPR/Cas13 system, they were able to specifically suppress the replication of the hepatitis E virus in human cells. Hepatitis E is a common cause of acute liver inflammation worldwide, yet effective specific therapies are still lacking. The team has now demonstrated that the virus can be targeted using an RNA-directed CRISPR system. The results, published on May 4, 2026, in the journal JHEP Reports, open new perspectives for the development of antiviral strategies.

Why only some patients get liver disease: New protein pathway may help forecast alpha1-antitrypsin outcomes

Alpha1-antitrypsin deficiency, an inherited disorder affecting 100,000 people in the U.S., causes a progressive and incurable lung disease. A subset of patients with the condition—about 10% to 15%—also develop liver disease because of the accumulation of the aggregated protein variant resulting from the genetic error that causes the disease. Now, researchers at Washington University School of Medicine in St. Louis have identified a previously unknown biological process that helps explain why only a subset of the affected population develop liver disease.

Wealth and health divide: Obesity rates plateau in rich nations but surge in developing world

Obesity has long been the invisible health crisis looming over humanity, with rates climbing globally. There is some positive news now emerging from a multi-decade study spanning several nations. A recent study published in Nature by the Non-Communicable Disease Risk Factor Collaboration (NCD-RisC), a global network of health scientists, analyzed obesity-related data from 232 million people aged 5 years or older, spanning 45 years.

Just two radiotherapy sessions given over eight days can treat prostate cancer without any extra side effects

Two larger doses of radiotherapy for prostate cancer cause no additional side effects compared to the standard five doses of radiotherapy, according to results presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026). Experts say the research brings us one step closer to safe and effective radiotherapy in only two out-patient sessions.